How many stocks are there of Opthea?
The current number of stocks of Opthea is 1.22 B undefined.
Opthea Stocks 2025
Opthea Stocks
1.22 B
Ticker
OPT.AX
ISIN
AU000000OPT2
WKN
A2AB8J
In 2025, Opthea had 1.22 B outstanding stocks, a 91.9% change from the 638.2 M stocks in the previous year.
The Opthea Stocks history
| YEAR | NUMBER OF STOCKS (B USD) |
|---|---|
| 2031e | 1.22 |
| 2030e | 1.22 |
| 2029e | 1.22 |
| 2028e | 1.22 |
| 2027e | 1.22 |
| 2026e | 1.22 |
| 2025 | 1.22 |
| 2024 | 0.64 |
| 2023 | 0.51 |
| 2022 | 0.4 |
| 2021 | 0.37 |
| 2020 | 0.26 |
| 2019 | 0.23 |
| 2018 | 0.2 |
| 2017 | 0.16 |
| 2016 | 0.15 |
| 2015 | 0.11 |
| 2014 | 0.05 |
| 2013 | 0.05 |
| 2012 | 0.05 |
| 2011 | 0.05 |
| 2010 | 0.05 |
| 2009 | 0.05 |
| 2008 | 0.04 |
| 2007 | 0.04 |
| 2006 | 0.04 |
Opthea shares outstanding
The number of shares was Opthea in 2024 — This indicates how many shares 638.203 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Loading chart...
Number of stocks
Details
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Opthea earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Opthea's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Opthea’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Opthea's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
Opthea Aktienanalyse
What does Opthea do?
Opthea Ltd is a biopharmaceutical company specializing in the development of novel therapies for various eye diseases. The company was founded in 1985 in Melbourne, Australia as a spin-off from the Burnet Institute for Medical Research and Public Health. Since then, Opthea has become a leading company in ophthalmology and is researching innovative therapies that have the potential to improve the lives of millions of patients worldwide. Opthea's business model is to develop novel therapies for various eye diseases and market these therapies through partnerships with established pharmaceutical companies. The company focuses on developing therapies based on the inhibition of growth factors and other signaling pathways that promote the development of abnormal blood vessels and inflammation. This therapeutic principle offers a promising way to effectively treat various eye diseases. Opthea specializes in developing therapies for the treatment of wet age-related macular degeneration (AMD), which is the leading cause of severe visual impairment in older people. Opthea is developing a therapy aimed at inhibiting the excessive formation of blood vessels in the macula of the eye, which can impair vision. The drug called OPT-302 is used in combination therapies with existing treatments for wet AMD and has the potential to slow down the progression of the disease and improve vision. In addition to the therapy for wet AMD, Opthea is also researching therapy options for other eye diseases such as diabetic retinopathy, retinal vein occlusion, and corneal diseases. Opthea has filed numerous patents in this field and collaborates with various academic and clinical partners to advance the development of innovative therapies. Another important component of Opthea's business model is collaboration with established pharmaceutical companies. In 2020, Opthea entered into a licensing agreement with the pharmaceutical company Novartis, which includes exclusive distribution and marketing rights for the drug OPT-302 in Europe, Japan, and other countries outside of North America. This partnership allows Opthea to benefit from collaboration with an experienced and established partner while maximizing the potential of its innovative therapy. In summary, Opthea is a promising company in ophthalmology that specializes in the development of innovative therapies for various eye diseases. The company works closely with academic and clinical partners and leverages the advantages of partnerships with established pharmaceutical companies to maximize the potential of its therapies. With the therapy for wet AMD already in the pipeline, Opthea is expected to develop further therapy options in the future that will contribute to improving the lives of millions of patients worldwide. Opthea ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Opthea's Shares Outstanding
Opthea's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Opthea’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Opthea’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Opthea’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Opthea stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Opthea are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Opthea evolved in recent years?
The number of shares of Opthea has increased by 91.9% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Opthea as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Opthea?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Opthea pay?
Over the past 12 months, Opthea paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Opthea is expected to pay a dividend of 0 USD.
What is the dividend yield of Opthea?
The current dividend yield of Opthea is .
When does Opthea pay dividends?
Opthea pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Opthea?
Opthea paid dividends every year for the past 0 years.
What is the dividend of Opthea?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Opthea located?
Opthea is assigned to the 'Health' sector.
Wann musste ich die Aktien von Opthea kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Opthea from 2/24/2005 amounting to 0.15 USD, you needed to have the stock in your portfolio before the ex-date on 2/4/2005.
When did Opthea pay the last dividend?
The last dividend was paid out on 2/24/2005.
What was the dividend of Opthea in the year 2024?
In the year 2024, Opthea distributed 0 USD as dividends.
In which currency does Opthea pay out the dividend?
The dividends of Opthea are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Opthea
Our stock analysis for Opthea Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Opthea Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
